investors
investors
Dr. Lalonde: From two years and 25 scientists...
Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months "When I...
investors
Dr. Lalonde: Invizyne [...] helps the...
"Invizyne is taking what nature has done and [...] putting things in a manufacturing format so we...
investors
Commercializing Invizyne’s cell-free platform -...
Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice...
investors
Invizyne IPO - KOL Call with Dr. James J....
MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a...
investors
Invizyne presented by Michael Heltzen & Tyler...
In this video, CEO of Invizyne, Michael Heltzen - and VP of Research, Tyler Korman, PhD -...
investors
Invizyne presented by Chris Marlett
In this video, CEO of MDB Capital Holdings, Chris Marlett, presents Invizyne. Invizyne is a...